Breast Cancer

, 6:275 | Cite as

Molecular pathology of Breast Cancer: Prognostic and predictive markers in this century and the next

  • Diana M. Barnes
Special Lecture

Key words

Immunohistochemistry SPF Prediction Prognostic Response 



Estrogen receptor


S-phase fraction




Enzyme immunoassay


Imperial Cancer Research Fund


Ductal carcinomain situ


Comparative genomic hybridization


Fluorescentin situ hybridization


  1. 1).
    Jensen EV, DeSombre ER: Steroid hormone binding and hormone receptor. In: Holland JF, Frie E, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR eds, Cancer Medicine, Lea & Febinger, Philadelphia, pp815–823, 1993.Google Scholar
  2. 2).
    Barnes DM, Harris WH, Smith P,et al: Immunohistochemical determination of oestrogen receptor; Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients.Br J Cancer 74:1445–1451, 1996.PubMedGoogle Scholar
  3. 3).
    Miles DW, Harris WH, Gillett CE,et al: The effect of cerbB2 and oestrogen receptor status on survival of women with primary breast cancer treated with adjuvant CMF. Int J Cancer 84:354–359, 1999.PubMedCrossRefGoogle Scholar
  4. 4).
    Gillett C, Fantl V, Smith R,et al: Amplification and overexpression of cyclin Dl in breast cancer detected by immunohistochemical staining.Cancer Res 54:1812–1817, 1994.PubMedGoogle Scholar
  5. 5).
    Gillett C, Smith P, Gregory W,et al:Cyclin Dl and prognosis in human breast cancer.Int J Cancer 69:92–99, 1996.PubMedCrossRefGoogle Scholar
  6. 6).
    Fredersdorf S, Burns J, Milne AM,et al: High level expression of p27kipl in proliferating tumour cells and its inverse correlation with the degree of malignancy in human breast colorectal tumours.Proc Natl Acad Sci USA 94:6380–6385, 1997.PubMedCrossRefGoogle Scholar
  7. 7).
    Gillett CE, Smith P, Peters G,et al: Cyclin dependent kinase inhibitor p27kipl expression and interaction with other cell cycle associated proteins in mammary carcinoma.J Pathol 187:200–206, 1999.PubMedCrossRefGoogle Scholar
  8. 8).
    Gullick WJ, Love SB, Wright C,et al: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.Br J Cancer 63:434–438, 1991.PubMedGoogle Scholar
  9. 9).
    Barnes DM, Dublin EA, Fisher CJ,et al: Immunohistochemical detection of p53 protein in mammary carcinoma; An important new independent indicator of prognosis.Human Pathol 24:469–476, 1993.CrossRefGoogle Scholar
  10. 10).
    Dublin EA, Miles DW, Rubens RD,et al: p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer.Int J Cancer (Pred Oncol) 74:605–608, 1997.CrossRefGoogle Scholar
  11. 11).
    Camplejohn RS, Ash C, Gillett CE,et al: The prognostic significance of DNA flow cytometry in breast cancer; Results from 881 patients treated in a single centre.Br J Cancer 71:140–145, 1995.PubMedGoogle Scholar
  12. 12).
    Korenman SG, Dukes BA: Specific estrogens binding by the cytoplasm of human breast carcinoma.Clin Endocrinol Metab 30:639–645, 1970.Google Scholar
  13. 13).
    Cooper LS, Gillett CE, Smith PE,et al: Cell proliferation measured by MIB1 and timing of surgery for breast cancer.Br J Cancer 77:1502–1507, 1998.PubMedGoogle Scholar
  14. 14).
    O’Reilly SM, Camplejohn RS, Barnes DM,et al: Nodenegative breast cancer; Prognostic subgroups defined by tumour size and flow cytometry.J Clin Oncol 8:2040–2046, 1990.PubMedGoogle Scholar
  15. 15).
    Nielsen NH, Emdin SO, Cajander J,et al: De-regulation of cyclin E and Dl in breast cancer is associated with inactivation of the retinoblastoma protein.Oncogene 14:295–304, 1997.PubMedCrossRefGoogle Scholar
  16. 16).
    Barnes DM, Gillett CE: Cyclin Dl in breast cancer.Br Cancer Res Treat 52:1–15, 1998.CrossRefGoogle Scholar
  17. 17).
    Barnes DM, Lammie GA, Millis RR,et al: An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.Br J Cancer 58:448–452, 1988.PubMedGoogle Scholar
  18. 18).
    Barnes DM: c-erbB-2 amplification in mammary carcinoma.J Cell Biochem 17G:132–138, 1993.CrossRefGoogle Scholar
  19. 19).
    Bartkova J, Barnes DM, Millis RR,et al: Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.Human Pathol 21:1164–1167, 1990.CrossRefGoogle Scholar
  20. 20).
    Barnes DM, Bartkova J, Camplejohn RS,et al: Overexpression of the c-erbB-2 oncoprotein; Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance.Eur J Cancer 28:644–648, 1992.PubMedCrossRefGoogle Scholar
  21. 21).
    Barnes DM, Camplejohn RS: p53, apoptosis and breast cancer.J Mam Gland Biol Neo 1:163–175, 1996.CrossRefGoogle Scholar
  22. 22).
    Houston SJ, Plunkett TA, Barnes DM,et al: Overexpression of c-erbB2 is a marker of resistance to endocrine therapy in advanced breast cancer.Br J Cancer 79:1220–1226, 1999.PubMedCrossRefGoogle Scholar
  23. 23).
    Allred DC, Harvey JM, Berardo M,et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis.Mod Pathol 11:155–169, 1998.PubMedGoogle Scholar
  24. 24).
    Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer; An overview of the randomised trials.Lancet 351:1451–1467, 1998.CrossRefGoogle Scholar
  25. 25).
    Baselga J, Seidman AD, Rosen PP,et al: HER2 overexpression and paclitaxel sensitivity in breast cancer; Therapeutic implications.Oncology ll(Suppl 2):43–48, 1997.Google Scholar
  26. 26).
    Yu D, Liu B, Tan M,et al: Overexpression of c-erbB2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.Oncogene 13:1359–1365, 1996.PubMedGoogle Scholar
  27. 27).
    Slamon D, Leyland-Jones B, Shak S,et al: Addition of herceptin (humanised anti-her2 antibody) to first line chemotherapy for her2 overexpressing metastatic breast cancer multinational controlled phase III trial.Proceedings of the American Society of Clinical Oncology 17:98a, 1998.Google Scholar
  28. 28).
    Cardiff RD: Cellular and molecular aspects of neoplastic progression in the mammary gland.Eur J Cancer 24:15–21, 1988.CrossRefGoogle Scholar
  29. 29).
    Lampejo OT, Barnes DM, Smith P,et al: Evaluation of infiltrating ductal carcinomas with a DCIS component; Correlation of the histological type of the in situ component with grade of the infiltrating component.Semin Diag Pathol 11:215–222, 1994.Google Scholar
  30. 30).
    Millis RR, Barnes DM, Lampejo OT,et al: Does mammary tumour grade progress?; A study of the correlation between DCIS type, tumour grade and grade of recurrent breast carcinoma.Eur J Cancer 34:548–553, 1998.PubMedCrossRefGoogle Scholar
  31. 31).
    Roylance R, Gorman P, Harris W,et al: Comparative genomic hybridisation of breast tumours stratified by histological grade reveals new insights into the biological progression of breast cancer.Cancer Res 59:1433–1436, 1999.PubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 1999

Authors and Affiliations

  • Diana M. Barnes
    • 1
  1. 1.Hedley Atkins/ICRF Breast Pathology Laboratory, Guy’s HospitalLondon

Personalised recommendations